 | Up a level |
2022
Rosenkranz, Stephan, Feldman, Jeremy, McLaughlin, Vallerie V., Rischard, Franz 
ORCID: 0000-0002-6861-8304, Lange, Tobias J., White, R. James, Peacock, Andrew J., Gerhardt, Felix, Ebrahimi, Ramin, Brooks, Gabriel, Satler, Carol and Frantz, Robert P.
(2022).
Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Resp. Med., 10 (1).
S. 35 - 47.
OXFORD:
ELSEVIER SCI LTD.
ISSN 2213-2600
2021
Hoeper, Marius M., Al-Hiti, Hikmet, Benza, Raymond L., Chang, Sung-A, Corris, Paul A., Gibbs, J. Simon R., Grunig, Ekkehard, Jansa, Pavel ORCID: 0000-0002-3711-7064, Klinger, James R., Langleben, David, McLaughlin, Vallerie V., Meyer, Gisela M. B., Ota-Arakaki, Jaquelina, Peacock, Andrew J., Pulido, Tomas, Rosenkranz, Stephan, Vizza, Carmine Dario ORCID: 0000-0002-3540-4983, Vonk-Noordegraaf, Anton, White, R. James, Chang, Mikyung, Kleinjung, Frank, Meier, Christian, Paraschin, Karen, Ghofrani, Hossein Ardeschir and Simonneau, Gerald
(2021).
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Lancet Resp. Med., 9 (6).
S. 573 - 585.
OXFORD:
ELSEVIER SCI LTD.
ISSN 2213-2600
2020
Simonneau, Gerald, Ghofrani, Hossein-Ardeschir, Corris, Paul A., Rosenkranz, Stephan, Gruenig, Ekkehard, White, Jim, McLaughlin, Vallerie V., Langleben, David, Meier, Christian, Busse, Dennis, Kleinjung, Frank and Benza, Raymond L. (2020). Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study. Pulm. Circ., 10 (4). THOUSAND OAKS: SAGE PUBLICATIONS INC. ISSN 2045-8940
2019
McLaughlin, Vallerie V., Vachiery, Jean-Luc, Oudiz, Ronald J., Rosenkranz, Stephan, Galie, Nazzareno, Barbera, Joan A., Frost, Adaani E., Ghofrani, Hossein-Ardeschir, Peacock, Andrew J., Simonneau, Gerald, Rubin, Lewis J., Blair, Christiana, Langley, Jonathan and Hoeper, Marius M. (2019). Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. J. Heart Lung Transplant., 38 (12). S. 1286 - 1296. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1557-3117
White, R. James, Vonk-Noordegraaf, Anton, Rosenkranz, Stephan, Oudiz, Ronald J., McLaughlin, Vallerie V., Hoeper, Marius M., Gruenig, Ekkehard, Ghofrani, Hossein-Ardeschir, Chakinala, Murali M., Barbera, Joan A., Blair, Christiana, Langley, Jonathan and Frost, Adaani E. (2019). Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. Respir. Res., 20 (1). LONDON: BMC. ISSN 1465-993X
2017
McLaughlin, Vallerie V., Jansa, Pavel ORCID: 0000-0002-3711-7064, Nielsen-Kudsk, Jens E., Halank, Michael, Simonneau, Gerald, Gruenig, Ekkehard, Ulrich, Silvia ORCID: 0000-0002-5250-5022, Rosenkranz, Stephan, Gomez Sanchez, Miguel A., Pulido, Tomas, Pepke-Zaba, Joanna, Albert Barbera, Joan, Hoeper, Marius M., Vachiery, Jean-Luc, Lang, Irene, Carvalho, Francine, Meier, Christian, Mueller, Katharina, Nikkho, Sylvia and D'Armini, Andrea M.
(2017).
Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.
BMC Pulm. Med., 17.
LONDON:
BMC.
ISSN 1471-2466
2016
Hoeper, Marius M., McLaughlin, Vallerie V., Albert Barbera, Joan, Frost, Adaani E., Ghofrani, Hossein-Ardeschir, Peacock, Andrew J., Simonneau, Gerald, Rosenkranz, Stephan, Oudiz, Ronald J., White, R. James, Miller, Karen L., Langley, Jonathan, Harris, Julia H. N., Blair, Christiana, Rubin, Lewis J. and Vachiery, Jean-Luc (2016). Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Resp. Med., 4 (11). S. 894 - 902. OXFORD: ELSEVIER SCI LTD. ISSN 2213-2600